Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials
- 7 December 2013
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 21 (3) , 433-440
Abstract
Background and purpose: Dopamine agonists (DAs) are generally considered to be deprived of the highly dyskinetic effect of levodopa in Parkinson's disease (PD) patients. However, the risk for dyskinesia induced byDAmonotherapy and the contribution of clinically significant factors in the development of this disorder have never been systematically assessed.Methods: A systematic literature search was conducted for randomized, levodopa‐controlled trials ofDAs in earlyPD. A meta‐analysis was performed to calculate the combined odds ratio (OR) for dyskinesia. Meta‐regressions were subsequently performed on dyskinesiaORincluding individually as covariates the effects of mean disease duration, treatment duration andDAdose. In an additional analysis the effect of adjunct levodopa on the odds for dyskinesia was investigated.Results: DAmonotherapy resulted in an 87% lower risk for dyskinesia compared with treatment with levodopa (OR = 0.13, 95% confidence interval 0.09–0.19,P< 0.001). The risk for dyskinesia was independent of the dose ofDA, disease duration and treatment duration. A dose‐related pattern was revealed between adjunct levodopa in theDAgroup and dyskinesia. Nevertheless, the odds for dyskinesia in theDAgroup were constantly lower than in the levodopa group.Conclusion: InitialDAtreatment encompasses a lower risk for dyskinesia even after the unavoidable introduction of levodopa that increases the risk for dyskinesia in a dose‐related manner. As the dose and treatment duration withDAs are factors independent of the risk of dyskinesia, monotherapy withDAs in earlyPDis suggested at doses that ensure efficacy and delay the need for levodopa, always following an adequate evaluation of the risksDAs can pose in individual patients.Keywords
This publication has 39 references indexed in Scilit:
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysisParkinsonism & Related Disorders, 2009
- Levodopa‐induced dyskinesiasMovement Disorders, 2007
- Controlling the risk of spurious findings from meta‐regressionStatistics in Medicine, 2004
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.BMJ, 1993
- A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Lisuride, a dopamine agonist in the treatment of early Parkinson's diseaseNeurology, 1989
- The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.Journal of Neurology, Neurosurgery & Psychiatry, 1989